Sandoz To Acquire Aspen’s Japanese Operations
Up to €400m Deal Strengthens Hospitals Portfolio
Sandoz is to pay up to €400m for Aspen’s anesthetics and other specialty off-patent brands in Japan, strengthening the Novartis division’s local position in the hospitals market.
You may also be interested in...
Fresh from announcing the €642m ($762m) divestment of its Thrombosis business in Europe to Mylan, Aspen Pharmacare management walked investors through its full-year earnings, explaining in detail the company’s ambitions to focus on emerging markets.
Teva has announced a major strategic shift in Japan, with its Teva Takeda Pharma joint venture striking a deal to divest the majority of its traditional generics business to Nichi-Iko so that it can focus instead on complex generics and specialty products.
Having benefited financially from the increased demand from the coronavirus pandemic in the first quarter, Sandoz saw a reversal of fortune in Q2 as sales fell by more than one-tenth as reported, as the company explained to Generics Bulletin.